Combination therapy of bispecific antibodies against CEACAM5 and CD47 and bispecific antibodies against CEACAM5 and CD3

A bispecific antibody combination targeting CEACAM5 and CD47, alongside CEACAM5 and CD3, enhances tumor cell phagocytosis, addressing limitations in current cancer therapies by improving efficacy and safety for treating solid tumors.

JP2025523424APending Publication Date: 2025-07-23LAMKAP BIO BETA LTD
View PDF 22 Cites 0 Cited by

Patent Information

Application Number
JP2024573315
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-16
Filing Date
2023-06-15
Publication Date
2025-07-23

AI Technical Summary

Technical Problem

Current cancer treatments, including immunotherapies targeting CEA and CD47, face limitations in efficacy for solid tumors, with challenges such as tumor protection mechanisms, adverse effects, and low response rates, necessitating improved strategies to enhance tumor cell killing.

Method used

A combination therapy using bispecific antibodies that target both CEACAM5 and CD47, alongside CEACAM5 and CD3, to redirect macrophages for enhanced tumor cell phagocytosis, minimizing adverse effects by optimizing binding affinities and reducing immunogenicity.

Benefits of technology

The combination therapy significantly increases tumor cell killing efficacy, particularly in low CEACAM5-expressing tumors, with reduced side effects and improved progression-free and overall survival in patients with cancers like colorectal, lung, and gastric cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025523424000001_ABST
    Figure 2025523424000001_ABST
Patent Text Reader

Abstract

The present invention relates to bispecific antibodies that bind to human cancer fetal antigen CEACAM5 and human CD47, such combinations, and their use in the treatment of diseases, which are used for the treatment of cancer by bispecific antibodies that bind to human cancer fetal antigen CEACAM5 and human CD3ε. The present invention relates to bispecific antibodies (CEA×CD47 bispecific antibodies) that bind to human cancer fetal antigen five (CEACAM5, CEA) and human CD47, such combinations, and their use in the treatment of diseases, for use in the treatment of cancer in combination with bispecific antibodies (CEA×CD3 bispecific antibodies) that bind to CEA and human CD3ε, as described below.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Bispecific recombinant protein and use thereof

    EP3623388A1

  • Bispecific antibodies against ceacam5 and CD47

    EP3831849A1

  • Class I Anti-CEA Antibodies and Uses Thereof

    US20110064653A1

  • Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof

    US20140140989A1

  • Bispecific t cell activating antigen binding molecules

    US20140242079A1